BeyondSpring, Inc. · NASDAQ:BYSI
BeyondSpring — Investor Presentation (January 2021)
40 slides from BeyondSpring's investor presentation, January 2021
Slide 1: Corporate Presentation
Corporate Presentation JANUARY 2021 | NASDAQ: BYSI 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shal
Slide 3: BeyondSpring: Key Highlights
BeyondSpring: Key Highlights Committed to raising the standard of care for cancer patients in the largest global markets with first-in-class Mission treatments that improve lives and clinical outcomes for millions of patients in need 2 near-NDA Assets Global Capabilities Broad Pipeline Global Market
Slide 4: Experienced leadership team with 50+ product launches
Experienced leadership team with 50+ product launches LAN Huang, Ph.D. RAMON Mohanlal M.D., Ph.D. CEO and Founder Chief Medical Officer, EVP of R&D 无锡麦涛岚华 RICHARD Daly GORDON Schooley, Ph.D. Chief Operating Officer Chief Regulatory Officer ELIZABETH Czerepak, MBA JAMES Tonra, Ph.D. Chief Financial O
Slide 5: Strong network of advisors
Strong network of advisors Principal Investigator, CIN Study 105 & Study 106 DSMB Chairman, CIN Study 105 & Study 106 • Founding member and former Board Member of the NCCN • Chairman of NCCN Guidelines for Neutropenia Management in Guidelines for Neutropenia Management in U.S. U.S. • Former presiden
Slide 6: Two Near-term NDAs & robust drug development pipeline
Two Near-term NDAs & robust drug development pipeline Trial name / Commercial Indication Program Preclinical Phase 1 Phase 2 Phase 3 Status/Next Milestone collaborator rights CIN PROTECTIVE-1 Phase 3 primary endpoint met at interim analysis (All cancer, all (Study 105) China NDA U.S. NDA chemo) Plin
Slide 7: Plinabulin differentiated tubulin binding and its effect in DC maturation and GEF-H1 release
Plinabulin differentiated tubulin binding and its effect in DC maturation and GEF-H1 release published in Chem and Cell Reports 7
Slide 8: Plinabulin: first-in-class agent, stimulating innate and adaptive immune system
Plinabulin: first-in-class agent, stimulating innate and adaptive immune system (Proven Target: Immune Defense Protein GEF-H1) Plinabulin’s immune mechanism GEF-H1 activation2 designed to enable its effects in Plinabulin1 multiple cancer indications: Rho/ROCK ▪ Chemotherapy Induced activation1 Neutr
Slide 9: Triple Combo: Plinabulin + PD-1 + Radiation the Best Tumor Response
Triple Combo: Plinabulin + PD-1 + Radiation the Best Tumor Response in PD-1 non-responsive tumor model (MD Anderson) Tumor Volume (mm3) 2000 1000 0 DC activation within T cell analysis within the tumor (Day 30) the tumor (Day 30) Note: more data presented at AACR June 2020 9
Slide 10: Breakthrough Therapy Designation (US & China FDA) - NDA submission Q1 2021
Breakthrough Therapy Designation (US & China FDA) - NDA submission Q1 2021 Plinabulin + G-CSF in Chemotherapy-Induced Neutropenia (CIN) 10
Slide 11: Plinabulin will add value to a large and growing CIN market
Plinabulin will add value to a large and growing CIN market - PD-1 + chemo approved, so chemo will not go away Plinabulin + G-CSF in each cycle of chemo in non-myeloid cancers prevented or reduced the severity of neutropenia Chemotherapy remains U.S. Sales -- $4.5 Billion2 THE CORNERSTONE OF As a co
Slide 12: New CIN guidelines double the Addressable US Market
New CIN guidelines double the Addressable US Market CIN Prophylaxis Market dynamics post-guideline update • CIN guidelines modified in early 2020: Chemotherapy 650k3 patients/year – COVID-19 recognized as a universal risk factor – Prophylaxis now recommended for both high and INCREMENTAL HIGH interm
Slide 13: High unmet medical need even with SOC G-CSF
High unmet medical need even with SOC G-CSF CIN is a dangerous decrease in a patient’s white blood cell count. If Grade 4 neutropenia (ANC < 0.5x109 cells/L) is not treated, patients could die in first cycle of chemotherapy Short-term Outcome Benefit Long-term Outcome Benefit G-CSF monotherapy is su
Slide 14: Grade 4 neutropenia leads to fever, infection, chemo dose reduction and less survival
Grade 4 neutropenia leads to development of fever and infection; and to chemo dose reduction and less survival Grade 4 neutropenia was associated with fever Grade 4 neutropenia leads to dose reduction to (p = 0.04), documented infection (p < 0.0001), <85% of optimum dose → lower OS2 and bacteremia (
Slide 15: Plinabulin trials designed to maximize broad potential
Plinabulin trials designed to maximize broad potential: Plinabulin + G-CSF for all chemo in non-myeloid cancers Protective-2 Phase 3 Design (4 cycles of chemo treatment) Primary Endpoint: plinabulin (40 mg5) + pegfilgrastim (6 mg) • % prevent Grade 4 neutropenia (Cycle 1) N = 111 Single dose of plin
Slide 16: Plinabulin – G-CSF combination demonstrated over 100% better prevention of grade 4 neutropenia
Plinabulin – G-CSF combination demonstrated over 100% better prevention of grade 4 neutropenia in Cycle 1 Proportion of patients with prevention of grade 4 neutropenia in Cycle 1 p = 0.0015 31.5% 13.6% Plinabulin (40mg) + Neulasta (6mg) Neulasta (6mg) 16
Slide 17: PROTECTIVE-2 Phase 3 data: positive topline results
PROTECTIVE-2 Phase 3 data: positive topline results with statistical significance favoring the combination Key Efficacy Endpoints Results (combo n=111, pegfilgrastim n=110) Primary endpoint: Proportion of patients with prevention of • 31.5% vs. 13.6%, p=0.0015 Better safety profile in grade 4 neutro
Slide 18: Protective-2: Superior prevention of Profound Neutropenia with Combination vs G-CSF alone
Protective-2 (Phase 3): Superior prevention of Profound Neutropenia with Combination vs G-CSF alone Proportion of Patients with Profound Neutropenia Mean Duration (Days) of Profound Neutropenia (ANC< 0.1 x 109 cells/L) 0.8 Day (ANC< 0.1 x 109 cells/L) 0.8 50% 46.40% 0.6 Day 0.6 Day P-Value=0.0004 70
Slide 19: Potential for a broad Prevention of CIN label
Potential for a broad Prevention of CIN label: Plinabulin + G-CSF for all chemo in non-myeloid solid tumors The Premise ▪ Chemo kills fast dividing cells, which includes cancer cells, and white blood cells in bone marrow ▪ CIN is a problem with bone marrow, and not a problem with a specific type of
Slide 20: Plinabulin + G-CSF for CIN, NDA Submission in Q1 2021
Plinabulin+ G-CSF for CIN, NDA Submission in Q1 2021: Superior profile in a broad label: all chemo, non-myeloid solid tumor Plinabulin shown to statistically reduce Grade 4 neutropenia in 6 clinical trials (1,200+ patients) Registration Study Supporting Study Supporting Study Plinabulin + G-CSF comb
Slide 21: Chemotherapy without compromise: Turning the 4 Ds into the 4 Ss
Chemotherapy without compromise: Turning the 4 Ds into the 4 Ss DECREASED STABLE DOSE recommended dose maintaining >85% Plinabulin + G-CSF • Differentiated DELAYED SUSTAINED CYCLES clinical profile, cycles cycles on time potential to improve SOC DISCONTINUED STAY THE COURSE • Greater clinical chemot
Slide 22: Oncologists understand Plinabulin's potential to raise the SoC in CIN
Oncologists understand Plinabulin’s potential to raise the SoC in CIN Survey of 102 Board-certified U.S. Oncologists • Understanding of combination therapy: High • Likelihood to prescribe: High Comfort with Likelihood to use Plinabulin + G-CSF COMBINATION THERAPY COMBINATION THERAPY Favor to Strongl
Slide 23: Plinabulin + G-CSF: Breakthrough Therapy with potential to set a new SOC for CIN
Plinabulin + G-CSF: “Breakthrough Therapy” with potential to set a new SOC for CIN Opportunity Unmet need Product differentiation ✓Market size ✓Grade 4 neutropenia complications Plinablulin + G-CSF addresses 3 ✓Market growth ✓CIN: #1 reason for therapy change oncologist needs: ✓NCCN guideline change
Slide 24: Plinabulin in NSCLC - Final phase 3 topline anti-cancer data in 1H 2021
Plinabulin in NSCLC - Final phase 3 topline anti-cancer data in 1H 2021 24
Slide 25: Increasing incidence of non-small cell lung cancer (NSCLC)
Increasing incidence of non-small cell lung cancer (NSCLC) Key Investment Highlights: ▪ ~1.5M NSCLC diagnoses globally 2015 NSCLC market size by region1, 3 Global NSCLC market size and growth ($ billion)2 ▪ Key NSCLC drug sales (U.S., Japan, and major EU markets): ▪ $11.5B in 2017 23.6% $40 ▪ Increa
Slide 26: 2nd and 3rd line NSCLC (EGFR wild type): severe unmet clinical need
2nd and 3rd line NSCLC (EGFR wild type): severe unmet clinical need 2nd/3rd line NSCLC patients EGFR mutant EGFR wild type In EGFR wild type patients % of 2L/3L NSCLC patients (western) 15% 85% Much larger population mOS 18.3 months (TKI) 6-8 months (docetaxel) Much shorter OS SoC mOS 5.4 vs 8.2 mon
Slide 27: Approved therapies fail to address EGFR wild type NSCLC
Approved therapies fail to address EGFR wild type NSCLC (85% of Western patients) in 2nd and 3rd line treatment Only four therapies currently approved: Severe Unmet Medical Needs Moving into 1st line 2nd and 3rd lines Ramucirumab + Plinabulin + Nivolumab (PD-1) Pemetrexed docetaxel docetaxel vs. vs.
Slide 28: DUBLIN-3 (Study 103): Phase 3 in NSCLC hypothesis based on GEF-H1
DUBLIN-3 (Study 103): Phase 3 in NSCLC hypothesis based on Plinabulin IO mechanism on activating GEF-H1, a proven target GEF-H1 - higher GEF-H1 immune signatures associated with longer OS in cancer patient 1 • Anti-cancer activity • Augmentation of IO effect in combo with chemo or radiation, as anti
Slide 29: Post-hoc Phase 2 data from Plinabulin in NSCLC shows overall survival benefit
Post-hoc Phase 2 data from Plinabulin in NSCLC in mechanism targeted patients shows overall survival benefit • Plinabulin MoA- targeted patients: Measurable lung lesion with RECIST 1.1 (CT +4.6 months OS benefit scan > 1 cm in lung); 70% of (11.3 vs. 6.7) NSCLC HR = 0.76 • Improved QoL and well tole
Slide 30: DUBLIN-3 (Study 103): second interim analysis completed; DSMB recommended trial to continue
DUBLIN-3 (Study 103): Phase 3 in NSCLC – second interim analysis completed; DSMB recommended trial to continue DUBLIN-3 Phase 3 in NSCLC Trial Design Primary Endpoint: plinabulin (30 mg2) + Patients EGFR wild- docetaxel (75 mg/m2) • Overall Survival type NSCLC Secondary Endpoints: - MOA target patie
Slide 31: Plinabulin: pipeline in a drug for multiple cancer indications
Plinabulin: “pipeline in a drug” for multiple cancer indications Foundation Translation Transformation triple combo with IO + CIN + additional solid tumors radiation/chemo CIN indication (broad label) Safety demonstrated in >700 The “attractive” triple combo • 6 clinical trials confirm benefit patie
Slide 32: Near-term milestones will create significant value for Plinabulin in the next 12 to 36 months
Near-term milestones will create significant value for Plinabulin in the next 12 to 36 months ▪ CIN in global markets -> compelling value creation potential from improving SOC, and large opportunity for life cycle management Plinabulin life-cycle management related to ▪ NSCLC in global markets -> la
Slide 33: SEED is a majority-owned subsidiary pursuing Molecular Glue targeted protein degradation
SEED is a majority-owned subsidiary pursuing "Molecular Glue" targeted protein degradation to degrade disease- causing proteins previously believed to be undruggable • $800M collaboration with Lilly on three targets • Own targets (e.g., KRAS) • Structure conducive to having additional collaborations
Slide 34: BeyondSpring: Key Highlights
BeyondSpring: Key Highlights Committed to raising the standard of care for cancer patients in the largest global markets with first-in-class Mission treatments that improve lives and clinical outcomes for millions of patients in need 2 near-NDA Assets Global Capabilities Broad Pipeline Global Market
Slide 35: Appendix
Appendix ae BeyondSpring 35
Slide 36: Plinabulin – first-in-class agent (a 20-year journey)
Plinabulin – first-in-class agent (a 20-year journey) 2000-2005: NCE discovered 20 years ago from sea microbes, then optimized • In 2000, new chemical entity (NCE) Halamide class compound was discovered from sea microbes by Nereus Pharmaceuticals based in San Diego, CA • 300+ derivatives were made a
Slide 37: Plinabulin Registration Studies
NB Plinabulin Registration Studies SS DI A Q Study 101 Phase 1/2 Phase 2 Phase 3 Registration Phase 2 Efficacy Data Study 103 (DUBLIN-3) 4.6 month mOS extension Plinabulin + Docetaxel vs. Docetaxel Plinabulin + docetaxel vs. docetaxel in NSCLC, EGFR wild type in NSCLC anti- in Plinabulin MOA Primary
Slide 38: Plinabulin induces dendritic cell DC maturation, a key step in initiating anti-cancer immunotherapy
Plinabulin induces dendritic cell DC maturation, a key step in initiating anti-cancer immunotherapy ▪ The generation of cancer immunity is a cyclic process. In principle, the response of T cells to tumor cells should be amplified and expanded ▪ Initiating anti-cancer immunity includes antigen releas
Slide 39: Global neutropenia market
Global neutropenia market ▪ CIN market = $7 billion in 2017 (mainly used with high risk chemo) ▪ China and the U.S. represent 2/3 of all G-CSF global therapy ▪ Plinabulin positioning: Plinabulin as mono or combo therapy improves on the standard of care in the treatment of Chemotherapy Induced Neutro
Slide 40: APPENDIX
APPENDIX www.beyondspringpharma.com 40